APRE — Aprea Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1781983 ·
Last close
$0.76
Market Cap
$9.58M
52W High
$1.69
52W Low
$0.55
ADV30
426,313
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,032,180 | -3,591,304 | 42,289,924 | 41,233,428 | 3,819,663 |
| Mar 2026 | 0 | — | -3,430,412 | -3,287,917 | 47,612,387 | 46,466,202 | 6,024,007 |
| Dec 2025 | 0 | — | -2,643,093 | -2,455,630 | 15,933,401 | 14,599,347 | 3,491,719 |
| Sep 2025 | 0 | — | -3,117,388 | -2,972,410 | 14,321,316 | 13,718,052 | 3,408,468 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,020,002
Investing CF
$0
Financing CF
$39,208,538
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.54
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-336,929,358
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,578,666
Pretax Income TTM
$-11,954,827
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,185
EBITDA
$-13,201,041
Free Cash Flow
$-8,151,741
Enterprise Value
$-30,761,158
Total Cash
$41,233,428
Total Debt
$0
Shares Out
12,591,136
Trailing EPS
$-0.94
Book Value
$3.10
ROE
-46.1%
ROA
-27.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,233,836 | -12,599,569 | 15,933,401 | 3,491,719 | 12,441,682 | -12,894,439 |
| Dec 2024 | 0 | -14,319,655 | -12,958,711 | 23,979,493 | 4,672,038 | 19,307,455 | -13,556,718 |
| Dec 2023 | 0 | -15,471,963 | -14,286,756 | 22,650,174 | 5,696,668 | 16,953,506 | -12,177,608 |
| Dec 2022 | 0 | -37,372,044 | -112,662,027 | 30,155,827 | 4,512,149 | 25,643,678 | -25,011,136 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MDCX | Medicus Pharma Ltd. | $9.60M | $0.15 | — |
| BIOE | Bio Essence Corp | $9.79M | $0.18 | — |
| IMRN | Immuron Ltd | $9.36M | $1.16 | — |
| FBLG | FibroBiologics, Inc. | $9.25M | $1.39 | — |
| KALA | KALA BIO, Inc. | $9.21M | $0.48 | — |
News headlines (Yahoo Finance, 1h cache)
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
2026-09-22 12:30 · Yahoo
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:00 · Yahoo
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
2026-08-28 12:15 · Yahoo
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
2026-08-12 12:30 · Yahoo
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
2026-07-30 12:00 · Yahoo
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
2026-06-01 12:00 · Yahoo
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-13 10:30 · Yahoo
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
2026-04-01 12:30 · Yahoo
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
2026-03-30 12:00 · Yahoo
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
2026-03-30 12:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.